Patent ID: 9469876
Filing Date: 2016-10-18
CPC Classification: C12Q,G01N,Y02A

Claim Text:
1. A method of distinguishing metastatic prostate cancer from non-metastatic prostate cancer in a human patient comprising: a) isolating at least one microvesicle from a bodily fluid sample from the human patient by contacting the sample with at least one binding agent to one or more microvesicle surface antigens; b) isolating microRNA from the at least one microvesicle isolated in a); c) detecting the level of a plurality of microRNA within the microRNA isolated in b), wherein the plurality of microRNA comprises hsa-miR-574-3p (miR-574-3p), hsa-miR-200b (miR-200b), hsa-miR-375 (miR-375), hsa-miR-141 (miR-141), hsa-miR-331-3p (miR-331-3p) and hsa-miR-181a (miR-181a); d) comparing the level of each of the plurality of microRNA detected in c) to a reference; and e) classifying the sample as metastatic prostate cancer or non-metastatic prostate cancer based on the comparison in d).